BioVersys AG (XSWX:BIOV) ROIC %: -250.80% (As of Dec. 2025)


XSWX:BIOV BioVersys AG XSWX:BIOV
4 GF Score
Price CHF26.00
View Full Analysis

What is BioVersys AG ROIC %?

BioVersys AG XSWX:BIOV +1.17% 4 ROIC % is -250.80% as of Dec. 2025. GuruFocus rates XSWX:BIOV with a GF Score™ of 4/100.

ROIC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROC %. BioVersys AG's annualized return on invested capital (ROIC %) for the quarter that ended in Dec. 2025 was -250.80%.

As of today (2026-06-27), BioVersys AG's WACC % is 6.36%. BioVersys AG's ROIC % is -227.21% (calculated using TTM income statement data). BioVersys AG earns returns that do not match up to its cost of capital. It will destroy value as it grows.


BioVersys AG  (XSWX:BIOV) ROIC % Explanation

ROIC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROC %. The reason book values of debt and equity are used is because the book values are the capital the company received when issuing the debt or receiving the equity investments.

There are four key components to this definition. The first is the use of operating income or EBIT rather than net income in the numerator. The second is the tax adjustment to this operating income or EBIT, computed as a hypothetical tax based on an effective or marginal tax rate. The third is the use of book values for invested capital, rather than market values. The final is the timing difference; the capital invested is from the end of the prior year whereas the operating income or EBIT is the current year's number.

Why is ROIC % important?

Because it costs money to raise capital. A firm that generates higher returns on investment than it costs the company to raise the capital needed for that investment is earning excess returns. A firm that expects to continue generating positive excess returns on new investments in the future will see its value increase as growth increases, whereas a firm that earns returns that do not match up to its cost of capital will destroy value as it grows.

As of today, BioVersys AG's WACC % is 6.36%. BioVersys AG's ROIC % is -227.21% (calculated using TTM income statement data). BioVersys AG earns returns that do not match up to its cost of capital. It will destroy value as it grows.


Be Aware

Like ROE % and ROA %, ROIC % is calculated with only 12 months of data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.


BioVersys AG ROIC % Related Terms


BioVersys AG ROIC % Historical Data

* Premium members only.

The historical data trend for BioVersys AG's ROIC % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

BioVersys AG ROIC % Chart

BioVersys AG Annual Data
Trend Dec24 Dec25
ROIC %
-197.95 -242.15

BioVersys AG Semi-Annual Data
Jun24 Dec24 Jun25 Dec25
ROIC % 0.00 -176.36 -193.82 -250.80

XSWX:BIOV vs VRTX, REGN, ALNY: ROIC % Comparison

For the Biotechnology subindustry, BioVersys AG's ROIC %, along with its competitors' market caps and ROIC % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


BioVersys AG ROIC % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, BioVersys AG's ROIC % distribution charts can be found below:

* The bar in red indicates where BioVersys AG's ROIC % falls into.


XSWX:BIOV
4GF Score
BioVersys AG XSWX:BIOV
ROIC % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

BioVersys AG ROIC % Calculation

BioVersys AG's annualized Return on Invested Capital (ROIC %) for the fiscal year that ended in Dec. 2025 is calculated as:

ROIC % (A: Dec. 2025 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (A: Dec. 2024 ) + Invested Capital (A: Dec. 2025 ))/ count )
=-19.963 * ( 1 - 0% )/( (9.458 + 7.03)/ 2 )
=-19.963/8.244
=-242.15 %

where

BioVersys AG's annualized Return on Invested Capital (ROIC %) for the quarter that ended in Dec. 2025 is calculated as:

ROIC % (Q: Dec. 2025 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Jun. 2025 ) + Invested Capital (Q: Dec. 2025 ))/ count )
=-21.194 * ( 1 - 0% )/( (9.871 + 7.03)/ 2 )
=-21.194/8.4505
=-250.80 %

where

Note: The Operating Income data used here is two times the semi-annual (Dec. 2025) data. The tax rate is limited to between 0% and 100%.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about ROIC % →
What does a ROIC % of -250.80% mean?
BioVersys AG (XSWX:BIOV) has a ROIC % of -250.80% as of Dec. 2025. Return on invested capital is the ratio of current-period net income to average two-period invested capital. View historical data on BioVersys AG and its competitors.
Is BioVersys AG's ROIC % too high?
BioVersys AG's current ROIC % is -250.80%. Overall, BioVersys AG has a GF Score™ of 4/100, reflecting its overall financial health beyond just this single metric.
How does BioVersys AG's ROIC % compare to VRTX and REGN?
BioVersys AG's ROIC % of -250.80% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROIC % for a Biotechnology company?
A good ROIC % depends on the Biotechnology industry context. However, ROIC % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROIC % mean?
A high ROIC % can signal that a stock is expensive relative to its fundamentals. Return on invested capital is the ratio of current-period net income to average two-period invested capital. View historical data on BioVersys AG and its competitors. BioVersys AG's current ROIC % is -250.80%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BioVersys AG stock overvalued right now?
BioVersys AG (XSWX:BIOV) has a current ROIC % of -250.80%. The current ROIC % is -250.80%. BioVersys AG's overall GF Score™ is 4/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROIC % calculated?
ROIC % is calculated from a company's financial statements. For BioVersys AG (XSWX:BIOV), the current ROIC % is -250.80% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

BioVersys AG Business Description

Other Exchanges BIOVz:UKW33:Germany
Address c/o Technologiepark, Hochbergerstrasse 60c, Basel, CHE, CH-4057
BioVersys AG is a multi-asset, clinical-stage biopharmaceutical company. The Group focuses on research and development of novel antibacterial products for serious life-threatening infections caused by multi-drug resistant (MDR) bacteria. The pipeline products of the company include BV100 - novel MoA, Alpibectir - novel potentiator MoA, BV200 - novel anti-virulence MoA, BV500 - novel series, and others. It has one operating segment focusing on the research and development and prospective commercialization of antibiotics. Geographically, the company operates in Switzerland and France.
4GF Score

Get the complete analysis for XSWX:BIOV

ROIC % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

CHF26.00
Price